Text Size

Seroquel XR in the Long Term Treatment of Schizophrenia (SereNIS)

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
AstraZeneca
ClinicalTrials.gov Identifier:
NCT01202617
First received: September 14, 2010
Last updated: October 21, 2011
Last verified: October 2011
History of Changes
  Purpose

The purpose of the study is to determine whether the Seroquel XR treatment for 6 months improves the relapse prevention in schizophrenic outpatients


Condition
Relapse in Schizophrenia

Study Type: Observational
Study Design: Observational Model: Cohort
Time Perspective: Prospective
Official Title: Seroquel XR in the Long Term Treatment of Schizophrenia Focus on Affective Symptoms

Resource links provided by NLM:

MedlinePlus related topics: Schizophrenia
U.S. FDA Resources

Further study details as provided by AstraZeneca:

Primary Outcome Measures:
  • Rate of patients remained relapse free after 6 months of treatment [ Time Frame: on the 60th day of treatment ] [ Designated as safety issue: No ]
  • Rate of patients remained relapse free after 6 months of treatment [ Time Frame: on the 180th day of treatment ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • connection between relapse and affective symptoms [ Time Frame: on the 60th day of treatment ] [ Designated as safety issue: No ]
  • connection between relapse and affective symptoms [ Time Frame: 180th day of treatment ] [ Designated as safety issue: No ]

Enrollment: 1606
Study Start Date: September 2010
Study Completion Date: October 2011
Primary Completion Date: October 2011 (Final data collection date for primary outcome measure)
Groups/Cohorts
Schizophrenic outpatients between 18 & 70 years of age

  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

Psychiatric outpatients

Criteria

Inclusion Criteria:

  • schizophrenic outpatients on at least 600 mg Seroquel XR treatment for at least 1 month

Exclusion Criteria:

  • Severe cerebro- and cardiovascular disease, severe hepatic impairment, gravidity
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01202617

  Show 61 Study Locations
Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: Attila Nemeth National Psychiatric Centre
Study Chair: Lilla Szabo AstraZeneca
Study Director: Alexandra Henringh AstraZeneca
  More Information

No publications provided

Responsible Party: AstraZeneca
ClinicalTrials.gov Identifier: NCT01202617     History of Changes
Other Study ID Numbers: NIS-NHU-SER-2010/1
Study First Received: September 14, 2010
Last Updated: October 21, 2011
Health Authority: Hungary: National Institute of Pharmacy

Keywords provided by AstraZeneca:
Seroquel XR
schizophrenia
relapse prevention

Additional relevant MeSH terms:
Schizophrenia
Schizophrenia and Disorders with Psychotic Features
Mental Disorders
Quetiapine
Antipsychotic Agents
Tranquilizing Agents
 Central Nervous System Depressants
Physiological Effects of Drugs
Pharmacologic Actions
Central Nervous System Agents
Therapeutic Uses
Psychotropic Drugs

ClinicalTrials.gov processed this record on June 18, 2013